Longeveron (LGVN) Change in Account Payables (2020 - 2026)
Longeveron (LGVN) posted quarterly Change in Account Payables of -$130000.0 for Q1 2026, down 148.69% year-over-year from $267000.0 in Q1 2025, and up 80.18% quarter-over-quarter from -$656000.0 in Q4 2025.
Longeveron (LGVN) Change in Account Payables (2020 - 2026) Analysis & Trends
Longeveron's Change in Account Payables history runs 7 years deep, the most recent figure standing at -$130000.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 148.69% year-over-year to -$130000.0; the TTM figure through Mar 2026 stood at -$72000.0 (up 93.47% YoY), while the FY2025 annual figure was $325000.0, up 160.19% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$130000.0, up from -$656000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.2 million in Q2 2023, with the low at -$1.3 million in Q1 2023.
- The 5-year median for Change in Account Payables is -$7000.0 (2022), against an average of -$20705.9.
- Peak annual rise in Change in Account Payables reached 631.2% in 2023, while the deepest fall reached 18385.71% in 2023.
- Longeveron's Change in Account Payables stood at $1.1 million in 2022, then slumped by 116.65% to -$191000.0 in 2023, then sank by 312.57% to -$788000.0 in 2024, then gained by 16.75% to -$656000.0 in 2025, then surged by 80.18% to -$130000.0 in 2026.
- Business Quant data shows LGVN's Change in Account Payables at -$130000.0 in Q1 2026, -$656000.0 in Q4 2025, and $380000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 340,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 340,000.00 |
| Jun 30, 2026 | 340,000.00 |
| Mar 31, 2026 | -130,000.00 |
| Mar 31, 2026 | -130,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Dec 31, 2025 | -656,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Sep 30, 2025 | 380,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | 267,000.00 |
| Mar 31, 2025 | 267,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Dec 31, 2024 | -788,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | -867,000.00 |
| Jun 30, 2024 | -867,000.00 |
| Mar 31, 2024 | 829,000.00 |
| Mar 31, 2024 | 829,000.00 |